Sentence examples similar to sjc 1 from inspiring English sources

Table 2 Amplitudes and amplification factors at CB during the SSC Station SSC amplitude (nT) Amplification at CB KOU 43.4 1.67 SJC 56.4 1.28 JAT 54.6 1.33 CB 72.4 – EUS 49.8 1.45 SLZ 45.9 1.58 ALF 50.4 1.44 CB amplification is the ratio of the amplitude at the CB station to that at the other stations.

SJC <1 was achieved by 67 69 % of patients indicating that inflammation had mostly subsided.

Therefore, although most patients achieved TJC ≤1 and SJC ≤1, improvement of PGA-VAS is limited in the patients with longer disease duration (Fig.  3).

At baseline, current peripheral arthritis and/or enthesitis was more prevalent than dactylitis, as evidenced by the proportion of patients with a TJC ≥1, SJC ≥1, total enthesitis count ≥1, and dactylitis count ≥1.

By comparison, in our study, the mean changes from baseline to week 12 were -4.9 for TJC and -2.9 for SJC, and the median changes were lower than these mean changes (TJC, -3 and SJC, -1).

However, since the SJC was numerically lower in patients treated with TCZ (p=0.07, Kruskal Wallis test; table 3) and since progression of joint damage at low disease activity appears to be linked to SJC rather than CRP, 8 we performed an additional analysis looking at patients who did not attain a normal SJC (SJC>1).

During the first 12 months of follow-up (from T0 to T1), PsA subjects were classified as having achieved MDA when fulfilling 5 or more of the following 7 outcome measures at T1: TJC ≤1; SJC ≤1; PASI ≤1 or body surface area ≤3; VAS for pain ≤15; patient global disease activity VAS score of ≤20; HAQ ≤0.5 and tender entheseal points ≤1 [ 20].

By additionally entering five discriminatory MSUS parameters into the regression analysis a similar predictive model was derived, comprising five independent variables, which differed only in that a dichotomous power Doppler semi-quantitative score (total ≥1 for total of 16 scanned joints) replaced swollen joint count (SJC) ≥1 (Table 7).

In patients with an SJC ≥1 or TJC ≥1 at baseline, more patients had absence of swollen or tender joints (i.e., achieving an SJC or TJC equal to 0) by week 12 in the adalimumab group compared to the placebo group.

Patients were classified as having achieved minimal disease activity (MDA) only when fulfilling five of the following seven outcome measures at T1: TJC ≤1; SJC ≤1; PASI ≤1 or body surface area ≤3; VAS for pain ≤15; patient global disease activity VAS score of ≤20; HAQ ≤0.5 and tender entheseal points ≤1.

Even though there were three remission criteria fulfilled, 67 patients (80%) did not reach remission due to residual disease activity of PGH >1, another eight patients (9%) due to SJC >1, four patients (5%) due to TJC >1 and five patients (6%) due to CRP >1.